Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, has announced that its subsidiary Hotspur Technologies, Inc., which Teleflex acquired in June 2012, completed CE marking requirements to market the company’s Arrow ® GPSCath ® Balloon Dilatation Catheters to the European Union. These novel products enable multiple vascular procedures to be performed with one dual-function catheter, potentially reducing procedure time and expense for both patients and medical professionals.
The Arrow ® GPSCath ® Catheter is designed as a two-in-one device that incorporates the proprietary VisioValve ™ Injection System. This innovative combination enables physicians to perform high-pressure angioplasty and inject physician-specified fluids, such as contrast, all while maintaining the guidewire position.
“We are committed to enabling medical professionals to perform peripheral access procedures with devices that both simplify and improve the doctors’ and patients’ experiences,” said Benson Smith, Chairman, President and CEO of Teleflex. Added Smith, “There are approximately 20 million patients with peripheral vascular disease that could benefit from this multi-purpose approach to catheter design, and we are excited to bring this innovative peripheral access product to market. The Arrow ® GPSCath ® Balloon Dilatation Catheter with VisioValve ™ Technology is setting a higher bar for peripheral and dialysis access angioplasty performance.”
About Teleflex Incorporated
Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Limerick, PA, Teleflex employs approximately 11,700 people worldwide and serves healthcare providers in more than 140 countries. Additional information about Teleflex can be obtained from the company’s website at teleflex.com.